Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 7/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
| ▸ | CCKBR | P32239 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421955 | 0.74 | HTR6 (0.60) | HTTLMNAALDH1A1HTR6 | |
| SCHEMBL1422633 | 0.73 | ACLY (0.58) | ACLYHTR6METCCKBR | |
| SCHEMBL13211040 | 0.73 | HTR6 (0.52) | ACLYHTR6METCCKBR | |
| SCHEMBL1880552 | 0.72 | ACLY (0.52) | ACLYHTR6METCCKBR | |
| SCHEMBL1423219 | 0.72 | ACLY (0.56) | ACLYHTTHTR6CCKBR | |
| SCHEMBL1422226 | 0.72 | HTR6 (0.57) | HTR6 | |
| SCHEMBL1422181 | 0.70 | HTR6 (0.61) | ACLYHTR6 | |
| SCHEMBL1421968 | 0.70 | HTR6 (0.67) | HTR6 | |
| SCHEMBL9930450 | 0.70 | ACLY (0.57) | ACLYHTR6CCKBR | |
| SCHEMBL2035210 | 0.70 | ACLY (0.50) | ACLYHTR6CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105555-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DE. DR. ESTEVE, S.A. (ES) | 2011-05-05 | — | — | US | disclosed |
| EP-2116547-A1 | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105555-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | HTR6, HTR1A, HTR5A | ACLY 3936/4885MEN1 2258/4885KMT2A 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.